A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Novartis
Eastern Cooperative Oncology Group
Novartis
Novartis
Assiut University
Novartis
Baylor College of Medicine
SWOG Cancer Research Network
Novartis
American University of Beirut Medical Center
Hospices Civils de Lyon
European LeukemiaNet
Novartis
Novartis
Medical College of Wisconsin
Novartis
Gruppo Italiano Malattie EMatologiche dell'Adulto
University of Pisa
M.D. Anderson Cancer Center
University of Liverpool
University of Jena
Ascentage Pharma Group Inc.
Masaryk University
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Australasian Leukaemia and Lymphoma Group
Novartis
Novartis
Pfizer
Novartis
University of Jena
Novartis
Medical College of Wisconsin
UNC Lineberger Comprehensive Cancer Center
University Hospital, Bordeaux
Novartis
Novartis
Milton S. Hershey Medical Center
Weill Medical College of Cornell University
Kartos Therapeutics, Inc.
Shenzhen Second People's Hospital
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
Takeda
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis